Cue Health, a healthcare technology company developing diagnostic products, has raised over $45 million in Series B financing.
The San Diego-based company said the financing will be used to complete development and fund the initial set of FDA 510(k) clinical studies for its first set of diagnostic products.
The new investors in the round include Johnson & Johnson Innovation, Section 32, Dentsu Ventures, Synergy Ventures, Principles of Tarsadia Investments, Pritzker Group Venture Capital, Babel Ventures and Troy Capital. Returning investors include Sherpa Capital, Cove Investments and Rohan Oza.
“We are excited to partner with this group of investors who have strong expertise across medical diagnostics, regulatory affairs and consumer health; their strategic guidance will be invaluable as we move into this next phase of the business and continue to build our technological platform," said Ayub Khattak, founder and CEO of Cue Health. "The Cue team has done a great job in advancing our multi-disciplinary product development and processes, and we are thrilled to have our new partners’ support as we continue on our journey.”
healthcare, technology, investors, Cue Health, Ayub Khattak, US